牛牛AI助理已提取核心訊息
AbbVie Inc. officer Perry C Siatias is set to sell 2,919 shares of the company's common stock on February 2, 2024, according to a recent filing. The shares, valued at approximately $496,230, were acquired on the same date through the exercise of stock options, with the issuer being the source of the securities. The transaction involved a cash payment made on the date of acquisition. There have been no other reported sales of securities by Siatias in the past three months, as per the provided documentation.
AbbVie Inc. officer Perry C Siatias is set to sell 2,919 shares of the company's common stock on February 2, 2024, according to a recent filing. The shares, valued at approximately $496,230, were acquired on the same date through the exercise of stock options, with the issuer being the source of the securities. The transaction involved a cash payment made on the date of acquisition. There have been no other reported sales of securities by Siatias in the past three months, as per the provided documentation.
根據最近的一份文件，艾伯維公司高管佩裏·西亞蒂亞斯定於2024年2月2日出售該公司的2919股普通股。這些股票價值約496,230美元，於同日通過行使股票期權收購，發行人是證券的來源。該交易涉及在收購之日支付的現金。根據提供的文件，在過去三個月中，Siatias沒有報告過其他證券銷售情況。
根據最近的一份文件，艾伯維公司高管佩裏·西亞蒂亞斯定於2024年2月2日出售該公司的2919股普通股。這些股票價值約496,230美元，於同日通過行使股票期權收購，發行人是證券的來源。該交易涉及在收購之日支付的現金。根據提供的文件，在過去三個月中，Siatias沒有報告過其他證券銷售情況。
有用
沒用